Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Elevance Health Inc. debt to equity ratio deteriorated from Q1 2024 to Q2 2024 but then improved from Q2 2024 to Q3 2024 exceeding Q1 2024 level. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Elevance Health Inc. debt to capital ratio deteriorated from Q1 2024 to Q2 2024 but then improved from Q2 2024 to Q3 2024 exceeding Q1 2024 level. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Elevance Health Inc. debt to assets ratio deteriorated from Q1 2024 to Q2 2024 but then improved from Q2 2024 to Q3 2024 exceeding Q1 2024 level. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Elevance Health Inc. financial leverage ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Elevance Health Inc. interest coverage ratio improved from Q1 2024 to Q2 2024 but then deteriorated significantly from Q2 2024 to Q3 2024. |
Debt to Equity
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Short-term borrowings | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | 275) | 175) | 175) | —) | —) | 150) | —) | 1,075) | 700) | 710) | 1,010) | 1,095) | |||||||
Current portion of long-term debt | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | 1,599) | 849) | 849) | 700) | 700) | 1,599) | 1,603) | 1,603) | 1,598) | 700) | 850) | 851) | |||||||
Long-term debt, less current portion | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | 21,157) | 21,761) | 22,217) | 22,534) | 19,335) | 19,094) | 19,873) | 19,005) | 17,787) | 18,820) | 17,436) | 17,396) | |||||||
Total debt | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | 23,031) | 22,785) | 23,241) | 23,234) | 20,035) | 20,843) | 21,476) | 21,683) | 20,085) | 20,230) | 19,296) | 19,342) | |||||||
Shareholders’ equity | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | 36,060) | 35,737) | 34,968) | 33,853) | 33,199) | 33,921) | 34,455) | 31,693) | 31,728) | 31,332) | 30,793) | 29,998) | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to equity1 | 0.62 | 0.66 | 0.65 | 0.64 | 0.65 | 0.66 | 0.68 | 0.66 | 0.66 | 0.66 | 0.65 | 0.64 | 0.64 | 0.66 | 0.69 | 0.60 | 0.61 | 0.62 | 0.68 | 0.63 | 0.65 | 0.63 | 0.64 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 0.38 | 0.38 | 0.38 | 0.38 | 0.41 | 0.45 | 0.46 | 0.46 | 0.46 | 0.46 | 0.48 | 0.50 | 0.53 | 0.55 | 0.55 | 0.57 | 0.59 | 0.64 | 0.60 | 0.58 | 0.60 | 0.61 | 0.62 | |||||||
Cigna Group | 0.78 | 0.77 | 0.80 | 0.67 | 0.68 | 0.72 | 0.73 | 0.69 | 0.70 | 0.73 | 0.72 | 0.71 | 0.72 | 0.68 | 0.66 | 0.65 | 0.75 | 0.77 | 0.81 | 0.83 | 0.87 | 0.89 | 0.95 | |||||||
CVS Health Corp. | 0.87 | 0.89 | 0.87 | 0.81 | 0.83 | 0.88 | 0.82 | 0.74 | 0.74 | 0.73 | 0.76 | 0.75 | 0.79 | 0.81 | 0.87 | 0.93 | 0.97 | 1.05 | 1.10 | 1.07 | 1.10 | 1.16 | 1.25 | |||||||
Humana Inc. | 0.76 | 0.79 | 0.84 | 0.74 | 0.71 | 0.72 | 0.72 | 0.75 | 0.67 | 0.85 | 0.87 | 0.80 | 0.77 | 0.50 | 0.54 | 0.51 | 0.51 | 0.56 | 0.66 | 0.49 | 0.55 | 0.50 | 0.58 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.49 | 0.49 | 0.49 | 0.47 | 0.55 | 0.51 | 0.44 | 0.46 | 0.48 | 0.49 | 0.50 | 0.51 | 0.60 | 0.60 | 0.57 | 0.49 | 0.49 | 0.51 | 0.52 | 0.51 | 0.50 | 0.50 | 0.50 | |||||||
UnitedHealth Group Inc. | 0.83 | 0.84 | 0.85 | 0.70 | 0.75 | 0.80 | 0.87 | 0.74 | 0.65 | 0.71 | 0.65 | 0.64 | 0.67 | 0.70 | 0.70 | 0.66 | 0.67 | 0.72 | 0.91 | 0.71 | 0.82 | 0.80 | 0.74 |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 27,148 ÷ 43,775 = 0.62
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Elevance Health Inc. debt to equity ratio deteriorated from Q1 2024 to Q2 2024 but then improved from Q2 2024 to Q3 2024 exceeding Q1 2024 level. |
Debt to Capital
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Short-term borrowings | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | 275) | 175) | 175) | —) | —) | 150) | —) | 1,075) | 700) | 710) | 1,010) | 1,095) | |||||||
Current portion of long-term debt | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | 1,599) | 849) | 849) | 700) | 700) | 1,599) | 1,603) | 1,603) | 1,598) | 700) | 850) | 851) | |||||||
Long-term debt, less current portion | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | 21,157) | 21,761) | 22,217) | 22,534) | 19,335) | 19,094) | 19,873) | 19,005) | 17,787) | 18,820) | 17,436) | 17,396) | |||||||
Total debt | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | 23,031) | 22,785) | 23,241) | 23,234) | 20,035) | 20,843) | 21,476) | 21,683) | 20,085) | 20,230) | 19,296) | 19,342) | |||||||
Shareholders’ equity | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | 36,060) | 35,737) | 34,968) | 33,853) | 33,199) | 33,921) | 34,455) | 31,693) | 31,728) | 31,332) | 30,793) | 29,998) | |||||||
Total capital | 70,923) | 69,877) | 67,059) | 64,426) | 63,267) | 63,329) | 62,822) | 60,421) | 59,763) | 59,400) | 59,230) | 59,091) | 58,522) | 58,209) | 57,087) | 53,234) | 54,764) | 55,931) | 53,376) | 51,813) | 51,562) | 50,089) | 49,340) | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to capital1 | 0.38 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.40 | 0.40 | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.38 | 0.38 | 0.38 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 0.27 | 0.27 | 0.27 | 0.28 | 0.29 | 0.31 | 0.31 | 0.31 | 0.32 | 0.31 | 0.33 | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.37 | 0.39 | 0.38 | 0.37 | 0.38 | 0.38 | 0.38 | |||||||
Cigna Group | 0.44 | 0.44 | 0.44 | 0.40 | 0.41 | 0.42 | 0.42 | 0.41 | 0.41 | 0.42 | 0.42 | 0.42 | 0.42 | 0.40 | 0.40 | 0.40 | 0.43 | 0.44 | 0.45 | 0.45 | 0.46 | 0.47 | 0.49 | |||||||
CVS Health Corp. | 0.47 | 0.47 | 0.46 | 0.45 | 0.45 | 0.47 | 0.45 | 0.42 | 0.42 | 0.42 | 0.43 | 0.43 | 0.44 | 0.45 | 0.47 | 0.48 | 0.49 | 0.51 | 0.52 | 0.52 | 0.52 | 0.54 | 0.56 | |||||||
Humana Inc. | 0.43 | 0.44 | 0.46 | 0.42 | 0.41 | 0.42 | 0.42 | 0.43 | 0.40 | 0.46 | 0.46 | 0.44 | 0.43 | 0.33 | 0.35 | 0.34 | 0.34 | 0.36 | 0.40 | 0.33 | 0.35 | 0.33 | 0.37 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.33 | 0.33 | 0.33 | 0.32 | 0.35 | 0.34 | 0.31 | 0.31 | 0.32 | 0.33 | 0.34 | 0.34 | 0.37 | 0.37 | 0.36 | 0.33 | 0.33 | 0.34 | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | |||||||
UnitedHealth Group Inc. | 0.45 | 0.46 | 0.46 | 0.41 | 0.43 | 0.44 | 0.46 | 0.43 | 0.39 | 0.41 | 0.39 | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 | 0.48 | 0.41 | 0.45 | 0.44 | 0.43 |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= 27,148 ÷ 70,923 = 0.38
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Elevance Health Inc. debt to capital ratio deteriorated from Q1 2024 to Q2 2024 but then improved from Q2 2024 to Q3 2024 exceeding Q1 2024 level. |
Debt to Assets
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Short-term borrowings | 360) | 225) | 1,575) | 225) | —) | 265) | 265) | 265) | 265) | 175) | 275) | 275) | 175) | 175) | —) | —) | 150) | —) | 1,075) | 700) | 710) | 1,010) | 1,095) | |||||||
Current portion of long-term debt | 2,100) | 2,900) | 2,900) | 1,649) | 799) | —) | —) | 1,500) | 2,249) | 2,248) | 3,097) | 1,599) | 849) | 849) | 700) | 700) | 1,599) | 1,603) | 1,603) | 1,598) | 700) | 850) | 851) | |||||||
Long-term debt, less current portion | 24,688) | 24,561) | 21,976) | 23,246) | 24,045) | 24,859) | 25,201) | 22,349) | 21,258) | 21,165) | 19,883) | 21,157) | 21,761) | 22,217) | 22,534) | 19,335) | 19,094) | 19,873) | 19,005) | 17,787) | 18,820) | 17,436) | 17,396) | |||||||
Total debt | 27,148) | 27,686) | 26,451) | 25,120) | 24,844) | 25,124) | 25,466) | 24,114) | 23,772) | 23,588) | 23,255) | 23,031) | 22,785) | 23,241) | 23,234) | 20,035) | 20,843) | 21,476) | 21,683) | 20,085) | 20,230) | 19,296) | 19,342) | |||||||
Total assets | 116,533) | 112,988) | 111,894) | 108,928) | 110,478) | 109,168) | 109,040) | 102,772) | 103,026) | 100,877) | 100,486) | 97,460) | 98,060) | 96,097) | 95,683) | 86,615) | 86,574) | 87,976) | 82,399) | 77,453) | 77,809) | 75,851) | 74,523) | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Debt to assets1 | 0.23 | 0.25 | 0.24 | 0.23 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.23 | 0.24 | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 | 0.26 | 0.26 | 0.25 | 0.26 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 0.20 | 0.20 | 0.20 | 0.20 | 0.22 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | |||||||
Cigna Group | 0.21 | 0.21 | 0.21 | 0.20 | 0.21 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.22 | 0.23 | 0.24 | 0.24 | 0.25 | 0.25 | 0.26 | |||||||
CVS Health Corp. | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.26 | 0.24 | 0.23 | 0.23 | 0.24 | 0.24 | 0.24 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 | 0.30 | 0.31 | 0.31 | 0.31 | 0.33 | 0.34 | |||||||
Humana Inc. | 0.27 | 0.26 | 0.27 | 0.26 | 0.21 | 0.22 | 0.22 | 0.27 | 0.21 | 0.28 | 0.29 | 0.29 | 0.28 | 0.19 | 0.20 | 0.20 | 0.21 | 0.21 | 0.23 | 0.20 | 0.22 | 0.21 | 0.22 | |||||||
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
Medtronic PLC | 0.28 | 0.28 | 0.28 | 0.27 | 0.30 | 0.29 | 0.26 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | 0.31 | 0.31 | 0.31 | 0.27 | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.28 | |||||||
UnitedHealth Group Inc. | 0.26 | 0.26 | 0.26 | 0.23 | 0.22 | 0.23 | 0.25 | 0.23 | 0.20 | 0.22 | 0.21 | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 | 0.23 | 0.24 | 0.27 | 0.23 | 0.26 | 0.25 | 0.24 |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= 27,148 ÷ 116,533 = 0.23
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Elevance Health Inc. debt to assets ratio deteriorated from Q1 2024 to Q2 2024 but then improved from Q2 2024 to Q3 2024 exceeding Q1 2024 level. |
Financial Leverage
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Total assets | 116,533) | 112,988) | 111,894) | 108,928) | 110,478) | 109,168) | 109,040) | 102,772) | 103,026) | 100,877) | 100,486) | 97,460) | 98,060) | 96,097) | 95,683) | 86,615) | 86,574) | 87,976) | 82,399) | 77,453) | 77,809) | 75,851) | 74,523) | |||||||
Shareholders’ equity | 43,775) | 42,191) | 40,608) | 39,306) | 38,423) | 38,205) | 37,356) | 36,307) | 35,991) | 35,812) | 35,975) | 36,060) | 35,737) | 34,968) | 33,853) | 33,199) | 33,921) | 34,455) | 31,693) | 31,728) | 31,332) | 30,793) | 29,998) | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Financial leverage1 | 2.66 | 2.68 | 2.76 | 2.77 | 2.88 | 2.86 | 2.92 | 2.83 | 2.86 | 2.82 | 2.79 | 2.70 | 2.74 | 2.75 | 2.83 | 2.61 | 2.55 | 2.55 | 2.60 | 2.44 | 2.48 | 2.46 | 2.48 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 1.87 | 1.86 | 1.87 | 1.90 | 1.92 | 1.97 | 1.99 | 2.03 | 2.04 | 2.03 | 2.09 | 2.10 | 2.14 | 2.17 | 2.17 | 2.21 | 2.20 | 2.25 | 2.21 | 2.18 | 2.15 | 2.16 | 2.19 | |||||||
Cigna Group | 3.74 | 3.76 | 3.72 | 3.30 | 3.28 | 3.30 | 3.33 | 3.21 | 3.20 | 3.33 | 3.31 | 3.29 | 3.25 | 3.17 | 3.16 | 3.09 | 3.33 | 3.37 | 3.43 | 3.44 | 3.46 | 3.52 | 3.64 | |||||||
CVS Health Corp. | 3.37 | 3.37 | 3.38 | 3.27 | 3.38 | 3.44 | 3.35 | 3.21 | 3.27 | 3.06 | 3.15 | 3.10 | 3.16 | 3.16 | 3.24 | 3.32 | 3.38 | 3.46 | 3.54 | 3.48 | 3.52 | 3.57 | 3.68 | |||||||
Humana Inc. | 2.85 | 3.00 | 3.11 | 2.89 | 3.30 | 3.35 | 3.30 | 2.81 | 3.12 | 3.02 | 3.02 | 2.76 | 2.79 | 2.56 | 2.64 | 2.55 | 2.44 | 2.67 | 2.80 | 2.42 | 2.52 | 2.44 | 2.61 | |||||||
Intuitive Surgical Inc. | 1.14 | 1.13 | 1.13 | 1.16 | 1.17 | 1.17 | 1.16 | 1.17 | 1.15 | 1.14 | 1.13 | 1.14 | 1.13 | 1.13 | 1.14 | 1.15 | 1.15 | 1.16 | 1.16 | 1.18 | 1.18 | 1.17 | 1.17 | |||||||
Medtronic PLC | 1.75 | 1.75 | 1.77 | 1.77 | 1.83 | 1.80 | 1.71 | 1.73 | 1.75 | 1.76 | 1.78 | 1.81 | 1.92 | 1.91 | 1.87 | 1.79 | 1.79 | 1.80 | 1.81 | 1.79 | 1.78 | 1.78 | 1.79 | |||||||
UnitedHealth Group Inc. | 3.17 | 3.20 | 3.28 | 3.08 | 3.34 | 3.40 | 3.49 | 3.16 | 3.26 | 3.16 | 3.04 | 2.96 | 3.03 | 3.05 | 3.09 | 3.01 | 2.93 | 3.03 | 3.32 | 3.02 | 3.16 | 3.15 | 3.12 |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 116,533 ÷ 43,775 = 2.66
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Elevance Health Inc. financial leverage ratio decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Interest Coverage
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
Shareholders’ net income | 1,016) | 2,300) | 2,246) | 856) | 1,289) | 1,853) | 1,989) | 949) | 1,618) | 1,653) | 1,805) | 1,137) | 1,509) | 1,793) | 1,665) | 551) | 222) | 2,276) | 1,523) | 934) | 1,183) | 1,139) | 1,551) | |||||||
Add: Net income attributable to noncontrolling interest | (8) | 1) | 3) | (25) | 11) | 3) | 15) | 12) | (5) | (3) | (10) | (12) | (7) | 8) | 2) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
Add: Income tax expense | 365) | 685) | 690) | 170) | 354) | 585) | 615) | 193) | 533) | 493) | 531) | 275) | 494) | 552) | 509) | 60) | 167) | 873) | 566) | 164) | 306) | 314) | 394) | |||||||
Add: Interest expense | 300) | 280) | 265) | 259) | 259) | 261) | 251) | 229) | 213) | 208) | 201) | 200) | 201) | 205) | 192) | 191) | 198) | 201) | 194) | 190) | 185) | 184) | 187) | |||||||
Earnings before interest and tax (EBIT) | 1,673) | 3,266) | 3,204) | 1,260) | 1,913) | 2,702) | 2,870) | 1,383) | 2,359) | 2,351) | 2,527) | 1,600) | 2,197) | 2,558) | 2,368) | 802) | 587) | 3,350) | 2,283) | 1,288) | 1,674) | 1,637) | 2,132) | |||||||
Solvency Ratio | ||||||||||||||||||||||||||||||
Interest coverage1 | 8.52 | 9.07 | 8.70 | 8.49 | 8.87 | 9.76 | 9.95 | 10.13 | 10.75 | 10.71 | 11.01 | 10.93 | 10.04 | 8.03 | 9.09 | 8.96 | 9.59 | 11.16 | 9.14 | 9.02 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 12.65 | 11.74 | 11.46 | 11.46 | 10.79 | 11.34 | 13.06 | 15.89 | 18.41 | 20.07 | 18.10 | 16.41 | 16.38 | 14.28 | 12.77 | 10.10 | 7.66 | 6.80 | 7.39 | 7.09 | — | — | — | |||||||
CVS Health Corp. | 3.33 | 4.41 | 4.55 | 5.20 | 5.59 | 2.71 | 3.43 | 3.46 | 2.75 | 5.49 | 5.27 | 5.16 | 4.92 | 4.60 | 4.52 | 4.36 | 4.67 | 4.76 | 4.29 | 3.96 | — | — | — | |||||||
Humana Inc. | 3.98 | 5.02 | 6.03 | 7.73 | 9.48 | 10.19 | 10.30 | 9.89 | 10.31 | 11.61 | 11.27 | 11.49 | 10.87 | 11.78 | 18.22 | 17.52 | 22.25 | 19.81 | 15.36 | 15.34 | — | — | — | |||||||
Medtronic PLC | 8.87 | 8.97 | 9.90 | 9.43 | 10.15 | 11.02 | 10.88 | 10.98 | 10.95 | 10.18 | 5.65 | 5.21 | 3.68 | 4.02 | 6.60 | 4.71 | 4.12 | 3.84 | 3.76 | 4.60 | — | — | — | |||||||
UnitedHealth Group Inc. | 6.39 | 6.79 | 7.53 | 9.97 | 10.21 | 10.99 | 12.25 | 13.59 | 14.66 | 14.45 | 14.26 | 14.44 | 13.46 | 13.03 | 14.88 | 13.47 | 14.12 | 13.89 | 11.40 | 11.55 | — | — | — |
Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Interest coverage
= (EBITQ3 2024
+ EBITQ2 2024
+ EBITQ1 2024
+ EBITQ4 2023)
÷ (Interest expenseQ3 2024
+ Interest expenseQ2 2024
+ Interest expenseQ1 2024
+ Interest expenseQ4 2023)
= (1,673 + 3,266 + 3,204 + 1,260)
÷ (300 + 280 + 265 + 259)
= 8.52
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Elevance Health Inc. interest coverage ratio improved from Q1 2024 to Q2 2024 but then deteriorated significantly from Q2 2024 to Q3 2024. |